XML 57 R45.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note 3 - Summary of Significant Accounting Policies (Details Textual) - USD ($)
3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Feb. 12, 2016
Sep. 30, 2016
Sep. 30, 2015
Jun. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Dec. 31, 2015
Dec. 31, 2014
Feb. 16, 2016
Goodwill, Fair Value Disclosure                 $ 0
Fair Value Assumptions, Expected Dividend Rate         0.00%        
Derivative, Gain (Loss) on Derivative, Net   $ (938) $ (29,332)      
Goodwill, Impairment Loss   $ 404,169      
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount         9,215,816 4,801,112      
Options and Warrants [Member]                  
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount         6,418,887 4,801,112 5,111,111 4,371,111  
Convertible Preferred Shares [Member]                  
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount         2,796,929 0      
Private Placement [Member] | Series B Preferred Stock [Member] | Strategic Bio Partners [Member] | Debt Settlement [Member]                  
Class of Warrant or Right, Issued 295,945                
Private Placement [Member] | Series B Preferred Stock [Member] | Placement Agent Warrants [Member]                  
Class of Warrant or Right, Issued 127,346